RUA Life Sciences has provided a strong trading update for the 18-month period to September 2025, following the recent change to its year end. The company expects revenues for the period of £6.6m, c6% ahead of our estimate for the 18-months of c£6.2m, while for the 12-month period to September 2025, revenues were £5.1m versus our estimated £4.7m. For the 12-months to March 2025, the company expects an adjusted EBITDA of £0.5m (Cav estimate: £0.3m) and expects the full 18-month period to remain p ....
